Company intelligence / Profile preview

Kunshan RiboQuark Pharmaceutical Technology Co. Ltd.

Kunshan, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

RiboQuark is advancing QPI-1007, a synthetic siRNA targeting Caspase 2 for neuroprotection in NAION, in a global pivotal Phase II/III trial (QRK207) including sites in China. The trial evaluates visual function improvement via intravitreal injections; first patient dosed in China in 2017 with ongoing multinational enrollment.

Therapeutic areas: Ophthalmology
Modalities: Small interfering RNA
Industry: Biotech

Partnerships

Quark Pharmaceuticals Inc.Suzhou Ribo Life Science Co. Ltd.Ionis Pharmaceuticals (via Ribo)

Beyond the preview

Go deeper on Kunshan RiboQuark Pharmaceutical Technology Co. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kunshan RiboQuark Pharmaceutical Technology Co. Ltd..

Explore the full profile